Gunderson Dettmer has advised Faro AI. Faro AI, Inc. has raised $37.3 million in Series B financing round. The round was co-led Merck Global Health Innovation...
Faro AI Raises $37.3 Million in Series B Financing Round
Tarsus Pharmaceuticals Raises $125 Million in Oversubscribed PIPE Financing
Gunderson Dettmer has advised Tarsus Pharmaceuticals. Tarsus Pharmaceuticals (Nasdaq: TARS) (“Tarsus”) has announced that it has entered into a securities purchase agreement with qualified institutional buyers...
Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals
Gunderson Dettmer has advised Tarsus Pharmaceuticals. Latham & Watkins has advised Alkeus Pharmaceuticals. Tarsus Pharmaceuticals (Nasdaq: TARS) has entered into a definitive agreement to acquire Alkeus...
Osanni Bio Secures $190 Million in Series B Financing Led by Patient Square Capital
Gunderson Dettmer has advised Osanni Bio. Ropes & Gray has advised Patient Square Capital. Osanni Bio, a development-stage therapeutics platform, has completed a $190 million Series...
Contineum Therapeutics Prices $90 Million Upsized Public Equity Offering
Gunderson Dettmer has advised Contineum Therapeutics. Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum) a clinical-stage biopharmaceutical company, has announced the pricing of an upsized underwritten public offering...
The Owl AI Raises $11 Million in Series Seed Financing
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian has advised S32 on the deal. The Owl AI, a technology company developing an end-to-end AI-powered platform for sporting...
Cullinan Therapeutics’ $280 Million Private Placement
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Foresite Capital in the transaction. Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company,...
Contineum Therapeutics’ $110 Million IPO
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Contineum Therapeutics in the offering, and Sidley Austin represented the underwriters. Contineum Therapeutics, a clinical stage biopharmaceutical company,...
Tarsus Pharmaceuticals’ $115.0 Million Common Stock Offering
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian acted as counsel to Tarsus Pharmaceuticals in the offering, Hogan Lovells acted as regulatory counsel while Knobbe Martens Olson...
Veradigm’s $140 Million Acquisition of ScienceIO
McDermott Will & Emery represented Veradigm Inc. in the transaction, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented ScienceIO. Veradigm Inc. (NASDAQ: MDRX) (the “Company”),...
Natera’s $250 Million Follow-On Offering
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Natera, and Davis Polk & Wardwell advised the representatives of the several underwriters on the offering. Natera, Inc....